37 results on '"Hartung, H. -P."'
Search Results
2. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
3. Supplement to: The Guillain-Barré syndrome.
4. Bacteria and their cell wall components uniformly co-activate interleukin-17-producing thymocytes
5. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
6. Predictors of freedom from detectable disease activity in patients with clinically isolated syndrome treated with interferon beta-1b in the BENEFIT trial: EP1148
7. Active-controlled study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis (PREDICT study): OS4201
8. The CSF JCV antibody index for diagnosis of natalizumab-associated PML: OS2124
9. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview
10. T cell activation status determines the cytokine pattern induced by zymosan and bacterial DNA both in thymocytes and splenocytes
11. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG – the ICE study
12. G15 Switch of cerebral A1 adenosine receptor radioligand binding during phenoconversion of Huntington disease: a PET study
13. Re-expression of N-cadherin in remyelinating lesions of experimental inflammatory demyelination
14. Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS) patients with highly active disease despite therapy: SC345
15. Lymphocyte subset dynamics following alemtuzumab administration in the CARE-MS I trial: SC346
16. Changes to the adaptive immunity in blood and CSF during the long-term therapy with natalizumab: SC344
17. Monoclonal antibodies: MT 3-2
18. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients
19. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography
20. Natalizumab increases circulating CD34+ cells with an impaired functional potential in patients with multiple sclerosis. Bone marrow derived CD34+ cells remain unaffected: V732
21. Central nervous system involvement in patients with monoclonal gammopathy and polyneuropathy
22. Bioavailability of Interferon-beta in patients with multiple sclerosis - fishing for the surrogate
23. Clinical applications of intravenous immunoglobulins (IVIg) – beyond immunodeficiencies and neurology
24. Effects of long-term treatment with Natalizumab: V599
25. Current place of IVIG in other neurological disorders: SAT 2-3
26. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis
27. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference
28. TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME IS EXPRESSED IN THE INFLAMED PERIPHERAL NERVOUS SYSTEM
29. INTERLEUKIN-23 IN ACUTE INFLAMMATORY DEMYELINATION OF THE PERIPHERAL NERVOUS SYSTEM
30. Influence of age, gender, education and dexterity on upper limb motor performance in Parkinsonian patients and healthy controls
31. Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis
32. Autosomal dominant juvenile amyotrophic lateral sclerosis and distal hereditary motor neuronopathy with pyramidal tract signs: synonyms for the same disorder?
33. Despair of repair
34. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies
35. SCHWANN CELL SPECIFIC MECHANISMS OF IL-1 AUTOREGULATION IN VIVO
36. Sequential Expression of Transforming Growth Factor-β1 by T-cells, Macrophages, and Microglia in Rat Spinal Cord during Autoimmune Inflammation
37. A RING TRIAL OF IgM-ANTI-GM1: RESULTS AND RECOMMENDATIONS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.